Investment Analysts’ Weekly Ratings Changes for Revolution Medicines (RVMD)

A number of research firms have changed their ratings and price targets for Revolution Medicines (NASDAQ: RVMD):

• 11/6/2026 – Revolution Medicines had its price target raised by HC Wainwright from $280.00 to $350.00. They now have a “buy” rating on the stock.
• 11/5/2026 – Revolution Medicines had its price target raised by TD Cowen from $250.00 to $270.00. They now have a “buy” rating on the stock.
• 11/5/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $260.00 to $321.00. They now have an “outperform” rating on the stock.
• 11/5/2026 – Revolution Medicines had its price target raised by Piper Sandler from $210.00 to $222.00. They now have an “overweight” rating on the stock.
• 11/5/2026 – Revolution Medicines had its “buy” rating reaffirmed by Truist Financial. They now have a $261.00 price target on the stock, up from $241.00.
• 11/5/2026 – Revolution Medicines had its price target raised by Guggenheim from $275.00 to $298.00. They now have a “buy” rating on the stock.
• 10/21/2026 – Revolution Medicines had its “buy” rating reaffirmed by TD Cowen. They now have a $250.00 price target on the stock.
• 10/19/2026 – Revolution Medicines had its price target raised by Truist Financial from $240.00 to $241.00. They now have a “buy” rating on the stock.
• 10/16/2026 – Revolution Medicines is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – Revolution Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Revolution Medicines had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $275.00 price target on the stock.
• 10/14/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $259.00 to $260.00. They now have an “outperform” rating on the stock.
• 10/9/2026 – Revolution Medicines had its price target lowered by Bank of America from $265.00 to $264.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Revolution Medicines had its “buy” rating reaffirmed by TD Cowen.
• 10/8/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $251.00 to $259.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Revolution Medicines had its price target raised by Truist Financial from $239.00 to $240.00. They now have a “buy” rating on the stock.
• 9/28/2026 – Revolution Medicines is now covered by Brookline Capital Markets. They set a “buy” rating and a $318.00 price target on the stock.
• 9/24/2026 – Revolution Medicines is now covered by The Goldman Sachs Group. They set a “buy” rating and a $267.00 price target on the stock.
• 9/24/2026 – Revolution Medicines is now covered by The Goldman Sachs Group. They set a “buy” rating and a $267.00 price target on the stock.
• 9/21/2026 – Revolution Medicines had its price target raised by Bank of America from $225.00 to $265.00. They now have a “buy” rating on the stock.
• 9/10/2026 – Revolution Medicines is now covered by Morgan Stanley. They set an “overweight” rating and a $255.00 price target on the stock.
• 9/9/2026 – Revolution Medicines had its price target raised by Stifel Nicolaus from $215.00 to $230.00. They now have a “buy” rating on the stock.

Revolution Medicines Price Performance

Shares of RVMD stock traded up $14.97 during trading hours on Friday, hitting $192.62. The stock had a trading volume of 2,656,890 shares, compared to its average volume of 2,806,552. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The stock has a market capitalization of $41.29 billion, a price-to-earnings ratio of -21.14 and a beta of 1.44. Revolution Medicines, Inc. has a one year low of $58.91 and a one year high of $224.31. The stock’s 50-day moving average price is $197.46 and its two-hundred day moving average price is $157.18.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, beating analysts’ consensus estimates of ($2.35) by $0.45. The firm had revenue of $197.56 million for the quarter, compared to the consensus estimate of $25.58 million. During the same period in the previous year, the company posted ($1.61) earnings per share. Equities analysts forecast that Revolution Medicines, Inc. will post -8.94 EPS for the current year.

Insider Buying and Selling at Revolution Medicines

In other news, insider Mark Goldsmith sold 13,988 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $2,786,969.12. Following the completion of the transaction, the insider directly owned 253,342 shares in the company, valued at approximately $50,475,860.08. This represents a 5.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Margaret Horn sold 4,967 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $989,625.08. Following the completion of the transaction, the chief operating officer directly owned 149,680 shares of the company’s stock, valued at approximately $29,822,243.20. This trade represents a 3.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 290,991 shares of company stock worth $59,422,765. Company insiders own 7.60% of the company’s stock.

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.